Myriad Genetics (MYGN) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exagen (XGN) has outperformed Myriad Genetics (MYGN) over the past year, losing 25.6% versus a loss of 45.0%. Over five years, XGN leads with a -35.3% price change compared with -86.8% for MYGN. Myriad Genetics is the larger company by market cap ($405.1 million vs $203.1 million), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | XGN |
|---|---|---|
| Share price | $4.24 | $8.39 |
| Market cap | $405.08M | $203.13M |
| 1-day change | +0.83% | +2.63% |
| YTD return | -31.71% | +34.38% |
| 1-year return | -45.03% | -25.59% |
| 5-year return | -86.77% | -35.31% |
| EPS (TTM) | $-1.18 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.59 | $12.23 |
| 52-week low | $2.74 | $2.59 |
| Distance from 52-week high | -50.70% | -31.44% |
| Analyst consensus | hold | none |
| Avg. price target upside | -7.67% | +20.93% |
| Average volume | 2.04M | 331.27K |
| Shares outstanding | 95.65M | 24.23M |
| Employees | 2,700 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XGN has outperformed MYGN by 19.4 percentage points over the past year.
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
MYGN vs XGN FAQ
Which is bigger, Myriad Genetics or Exagen?
Myriad Genetics (MYGN) is larger, with a market capitalization of $405.08M compared with $203.13M for Exagen (XGN).
Which stock has performed better over the past year, MYGN or XGN?
XGN returned -25.59% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Myriad Genetics and Exagen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Myriad Genetics and Medical Specialities for Exagen.